
    
      This study is a prospective, exploratory clinical trial. The purpose of this study was to
      evaluate the efficacy and safety of apatinib monotherapy in the treatment of primary
      pulmonary lymphoepithelioid carcinoma.

      Thirty-three cases of pulmonary lymphoepithelioid carcinoma were enrolled in this study.

      The primary endpoint was median progression-free survival.
    
  